RemeGen Co Ltd, a leading biopharmaceutical company, is guided by a strong set of values and corporate philosophy. With a focus on innovation, RemeGen strives to develop and deliver high-quality and cutting-edge therapies to improve the lives of patients. Their commitment to integrity and ethical practices forms the foundation of their operations. RemeGen embraces a patient-centric approach, ensuring that their products address significant medical needs and contribute to the well-being of individuals. By fostering collaboration and nurturing talent, RemeGen places great importance on teamwork and continuous learning. With these values and corporate philosophy, RemeGen Co Ltd remains dedicated to making a positive impact in the healthcare industry.

RemeGen Co Ltd is primarily present in China.

RemeGen Co Ltd has achieved several significant milestones in its journey. Firstly, the company successfully developed three innovative antibody-based drugs targeting cancer and autoimmune diseases. This breakthrough in biopharmaceutical research highlights RemeGen's commitment to advancing medical treatments. Additionally, the company gained approval for its leading drug, RC48, to treat metastatic or locally recurrent triple-negative breast cancer, a major accomplishment in the field. Moreover, RemeGen forged strategic partnerships with top global pharmaceutical companies, fostering collaborations for research, development, and commercialization of its drugs. These milestones underscore RemeGen Co Ltd's dedication to revolutionizing healthcare and cement its position as a trusted leader in the industry.

RemeGen Co Ltd is a renowned biopharmaceutical company founded in 2008, headquartered in Yantai, China. With a focus on research, development, and commercialization of innovative therapies, RemeGen has made significant strides in the field of oncology. The company aims to address unmet medical needs and revolutionize treatment options for patients worldwide. RemeGen Co Ltd has earned recognition for its robust pipeline of potential breakthrough drugs, leveraging their expertise in monoclonal antibodies, antibody-drug conjugates, and fusion proteins. Their commitment to scientific excellence and dedication to improving patients' lives have established RemeGen as a leading player in the biopharmaceutical industry.

The main competitors of RemeGen Co Ltd in the market include a range of pharmaceutical companies operating in the same sector. Some notable competitors include BeiGene Ltd, Hengrui Medicine Co Ltd, and Junshi Biosciences Co Ltd. These companies, like RemeGen Co Ltd, are engaged in the research, development, and commercialization of innovative drugs and therapies. As a leading player in the pharmaceutical industry, RemeGen Co Ltd competes in various therapeutic areas, aiming to bring novel and effective treatments to the market.

RemeGen Co Ltd is primarily active in the pharmaceutical industry.

RemeGen Co Ltd is a biopharmaceutical company based in China. The business model of RemeGen Co Ltd primarily focuses on the research, development, and commercialization of innovative biologics for the treatment of various diseases. The company specializes in developing monoclonal antibodies and fusion proteins to target specific diseases, such as cancer and autoimmune disorders. RemeGen Co Ltd aims to provide effective and safe therapeutic options to patients in need, while also generating sustainable growth and creating value for its shareholders. With its dedication to advancing healthcare through biotechnology, RemeGen Co Ltd strives to positively impact patients' lives and contribute to the advancement of the global pharmaceutical industry.

RemeGen Co에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

RemeGen Co에 대한 현재 KUV는 계산할 수 없습니다.

RemeGen Co에 대한 AlleAktien 품질 점수는 3/10입니다.

RemeGen Co에 대한 현재 매출은 계산할 수 없습니다.

RemeGen Co의 현재 이익을 계산할 수 없습니다.

The company RemeGen Co Ltd is a biopharmaceutical company based in China that specializes in the development and commercialization of novel therapeutic antibodies. The company was founded in 2008 and is one of the leading companies in the biopharmaceutical industry. RemeGen is working on the development of antibodies with high efficacy and low risk of side effects. The company has developed a comprehensive pipeline that includes clinical trials for a variety of diseases, including cancer, autoimmune diseases, viral infections, and inflammation. The company's main product is IBI310, a monoclonal antibody specifically designed for the treatment of cancer patients. IBI310 fights cancer cells by selectively binding to the surface protein PD-L1 and triggering an immune response that destroys the cancer cells. The drug has the potential to revolutionize the treatment of cancer patients and is already being tested in clinical trials. RemeGen also offers projects in the field of novel antibody therapy for autoimmune diseases. The company has developed a pipeline of several potential therapeutics targeting various target molecules involved in autoimmune diseases. The company is also focused on the development of drugs to combat viral infections such as hepatitis B and C, as well as HIV. RemeGen's goal is to defeat these diseases and provide patients with a better quality of life. RemeGen is also a leading provider of biopharmaceutical services that support customers in conducting their research and product development. The company offers a wide range of services ranging from antibody design and development to cell line development and production, as well as analysis and characterization. RemeGen's business model is based on collaboration with other biopharmaceutical companies to jointly develop more innovative and effective therapies. The company has established strong partnerships with leading pharmaceutical companies such as Pfizer, Merck, and Roche. RemeGen's experience and expertise in the field of biopharmaceutical research and development have contributed to its position as one of the leading companies in this field. The company is continuously working to improve medical care and enhance the quality of life for patients.

RemeGen Co은(는) 연간 번의 배당을 통해 0 CNY의 배당금을 지급합니다.

RemeGen Co의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

RemeGen Co의 ISIN은 CNE1000048G6입니다.

RemeGen Co의 WKN은 A2QGM4입니다.

RemeGen Co의 티커는 9995.HK입니다.

지난 12개월 동안 RemeGen Co은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 RemeGen Co은(는) 0 CNY의 배당금을 지급할 것으로 예상됩니다.

RemeGen Co의 현재 배당 수익률은 입니다.

RemeGen Co은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

RemeGen Co은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 CNY의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

RemeGen Co은 '건강' 섹터에 속합니다.

RemeGen Co의 마지막 배당금을 0 CNY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 RemeGen Co는 0 CNY를 배당금으로 지급했습니다.

RemeGen Co의 배당금은 CNY에 지급됩니다.